Clinical Trial Update: A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression [Phase 2]

View source ↗

Summary

Phase 2 study of INCB123667 for platinum‑resistant ovarian cancer with Cyclin E1 overexpression is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• INCB123667 (INCB123667)

Snippet

Sponsor: Incyte Corporation | Conditions: Ovarian Cancer | Phase 2 | Status: RECRUITING